Clinical trials: Tumors, Breast
Breast Cancer
Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer
Clinical decision support has been shown to improve the performance of screening tests; however, few studies have documented direct clinical benefit resulting from the increased screening promoted by clinical decision support…
- Trial name
- NCT01336257
- Testing
- SEBASTIAN Clinical Decision Support System (CDSS)
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Hospital Italiano de Buenos Aires
Advanced Breast Cancer
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
Standard of care: Treatment with Trastuzumab Experimental: 21-Day Cycle of Combination therapy with T-DM1 intravenously on Day 1 and oral PD-0332991 on Days 5-18 Study Design and Methodology: This is a phase 1B inter-patient dose…
- Trial name
- NCT01976169
- Testing
- PD-0332991 and T-DM1
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer, Lung Cancer
Accountability for Cancer Care Through Undoing Racism and Equity
Purpose: African American cancer patients, as compared to their White counterparts, continue to initiate treatment later and remain less apt to undergo complete treatment; fueling worse treatment outcomes including shorter…
- Trial name
- ACCURE (NCT01954641)
- Testing
- ACCURE Navigator, Usual Care by Cancer Center Care Team
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of North Carolina, Chapel Hill
Breast Cancer Stage IV
Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients
Breast cancer is the commonest malignancy among females and one of the leading causes of death worldwide. Many drugs have been developed over the years to try to extend survival among these patients including cyclin dependant…
- Trial name
- NCT05670054
- Testing
- comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Mansoura University
Breast Cancer (Locally Advanced or Metastatic)
GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies…
- Trial name
- NCT07738341
- Testing
- GB268, Nab-Paclitaxel, Datopotamab Deruxtecan (Dato-DXd)
- Volunteers
- 270 people
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Metastatic Breast Cancer, Advanced Breast Cancer
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor positive (HR+) and have to be resistant to endocrine therapy and…
- Trial name
- ICARUS BREAST (NCT04965766)
- Testing
- U3-1402
- Where
- 11 sites in France
- Volunteers
- 139 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer
Comparison of Two Types of Biopsy in Patients With Breast Lesions
RATIONALE: Biopsy is the removal of cells or tissue for examination under a microscope. It is not yet known which type of breast biopsy is more effective for diagnosing breast lesions.
- Trial name
- NCT00006031
- Testing
- Needle localized breast biopsy with specimen x-ray, Low dose radioactive seed followed by surgery and mammogram
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Opt-in vs. Opt-out for Breast Cancer Screening
This is a randomized controlled trial that will evaluate the effectiveness two different outreach strategies for a population-based breast cancer screening program at the VA Puget Sound among average risk female Veterans who are…
- Trial name
- NCT05313737
- Testing
- Automated message, Opt-out scheduling
- Where
- United States
- Volunteers
- 871 people, healthy volunteers welcome
- Sponsor
- VA Puget Sound Health Care System
Breast Cancer
Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study
Evaluate the efficacy and safety of T-DXd in patients with HER2-positive and HER2-low metastatic breast cancer
- Trial name
- NCT07108595
- Testing
- T- Dxd
- Where
- China
- Volunteers
- 142 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Neoplasms
Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer Patients
Breast cancer surgery is associated with presurgical psychological distress and clinically significant side effects including postsurgical pain, nausea and fatigue.
- Trial name
- NCT02276404
- Testing
- relaxation training, acupuncture
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universität Duisburg-Essen
Early Breast Cancer
Aromatherapy in the Treatment of Early Breast Cancer
Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect.
- Trial name
- NCT06435104
- Testing
- neoadjuvant chemotherapy, aromatherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Exercise Preconditioning and Breast Cancer Cardiotoxicity
The purpose of this study is to determine whether a supervised exercise-training program, initiated prior to chemotherapy induction (pre-conditioning) and continued throughout chemotherapy treatment, can preserve short- and…
- Trial name
- EXACCT (NCT02842658)
- Testing
- A high-intensity interval exercise group, An Attention-Control Group
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor…
- Trial name
- NCT05361655
- Testing
- Palbociclib + an aromatase inhibitor, Aromatase inhibitor
- Where
- United States
- Volunteers
- 2,888 people
- Sponsor
- Pfizer
Breast Cancer
Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer
This is an open-label, multicenter randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide (FEC)-chemotherapy…
- Trial name
- NCT00670878
- Testing
- 3 x FEC 3 x DOC / Gemcitabine, 3 x FEC 3 x DOC
- Where
- Germany
- Volunteers
- 799 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Hormone-sensitive Metastatic Breast Cancer
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers.
- Trial name
- NCT01205685
- Testing
- OSI-906, Erlotinib, Letrozole
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of Inetetamab, an anti-HER2 monoclonal antibody with a…
- Trial name
- Increase (NCT04941885)
- Testing
- Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Immune Deficiency, Diet, Healthy
Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy
The purpose of the study was to investigate the impact of aerobic exercise combined with diet protocol on the immune system in post-mastectomy patients receiving chemotherapy.
- Conditions
- Immune Deficiency, Diet, Healthy, Breast Cancer
- Trial name
- NCT05605808
- Testing
- Aerobic exercises, Diet protocol
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Breast Cancer, Breast Neoplasms
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with trastuzumab (Herceptin) and in combination with trastuzumab and paclitaxel.
- Trial name
- NCT01042925
- Testing
- XL147 (SAR245408), trastuzumab, paclitaxel
- Where
- 9 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Sanofi
Breast Cancer
Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Conjugated Linoleic Acid (CLA) is obtained in the human diet by consumption of foods containing ruminant fat. Milk and dairy products have shown the highest amounts of CLA.
- Trial name
- NCT00908791
- Testing
- Conjugated Linoleic Acid (CLA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
The purpose of this clinical trial is to evaluate whether, in patients with hormone receptor-positive (HR-positive) and HER2-positive advanced breast cancer whose disease has progressed after trastuzumab-based therapy, switching…
- Conditions
- Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
- Trial name
- NCT07892274
- Testing
- Fulvestrant, Pyrotinib, Dalpiciclib
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.